{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT05737706","nct_id":"NCT05737706","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05737706. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Dose Escalation/Evaluation","label":"Phase 1/1B","type":"EXPERIMENTAL"},{"description":"MRTX1133 recommended Phase 2 dose administered to separate cohorts of patients with selected solid tumor malignancies with KRAS G12D mutation to include the following: NSCLC, PDAC, CRC, Other Solid Tumors","label":"Phase 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-03-10","type":"ACTUAL"},"conditions":["Solid Tumor","Advanced Solid Tumor","Non-small Cell Lung Cancer","Colo-rectal Cancer","Pancreatic Adenocarcinoma"],"enrollment":{"count":63,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"MRTX1133","otherNames":[],"type":"DRUG"}],"last_update":"2025-04-06","lead_sponsor":"Mirati Therapeutics Inc.","official_title":"A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2025-03-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Phase 1: Number of Patients who Experience Dose-Limiting Toxicity","timeFrame":"21 Days"},{"measure":"Phase 1/1b: Number of patients who experience a treatment-related adverse event","timeFrame":"Up to 2 years"},{"measure":"Phase 2: Objective response rate (ORR)","timeFrame":"2 years"},{"measure":"Phase 2: Duration of response (DOR)","timeFrame":"2 years"},{"measure":"Phase 2: Progression free survival (PFS)","timeFrame":"2 years"},{"measure":"Phase 2: Overall survival (OS)","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2023-03-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","url":"https://clinicaltrials.gov/study/NCT05737706"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05737706"}